Cargando…

Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics

Pancreatic cancer is one of the most lethal tumors, and reliable detection of early-stage pancreatic cancer and risk diseases for pancreatic cancer is essential to improve the prognosis. As 260 genes were previously reported to be upregulated in invasive ductal adenocarcinoma of pancreas (IDACP) cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoneyama, Toshihiro, Ohtsuki, Sumio, Honda, Kazufumi, Kobayashi, Makoto, Iwasaki, Motoki, Uchida, Yasuo, Okusaka, Takuji, Nakamori, Shoji, Shimahara, Masashi, Ueno, Takaaki, Tsuchida, Akihiko, Sata, Naohiro, Ioka, Tatsuya, Yasunami, Yohichi, Kosuge, Tomoo, Kaneda, Takashi, Kato, Takao, Yagihara, Kazuhiro, Fujita, Shigeyuki, Huang, Wilber, Yamada, Tesshi, Tachikawa, Masanori, Terasaki, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007017/
https://www.ncbi.nlm.nih.gov/pubmed/27579675
http://dx.doi.org/10.1371/journal.pone.0161009
_version_ 1782451155351109632
author Yoneyama, Toshihiro
Ohtsuki, Sumio
Honda, Kazufumi
Kobayashi, Makoto
Iwasaki, Motoki
Uchida, Yasuo
Okusaka, Takuji
Nakamori, Shoji
Shimahara, Masashi
Ueno, Takaaki
Tsuchida, Akihiko
Sata, Naohiro
Ioka, Tatsuya
Yasunami, Yohichi
Kosuge, Tomoo
Kaneda, Takashi
Kato, Takao
Yagihara, Kazuhiro
Fujita, Shigeyuki
Huang, Wilber
Yamada, Tesshi
Tachikawa, Masanori
Terasaki, Tetsuya
author_facet Yoneyama, Toshihiro
Ohtsuki, Sumio
Honda, Kazufumi
Kobayashi, Makoto
Iwasaki, Motoki
Uchida, Yasuo
Okusaka, Takuji
Nakamori, Shoji
Shimahara, Masashi
Ueno, Takaaki
Tsuchida, Akihiko
Sata, Naohiro
Ioka, Tatsuya
Yasunami, Yohichi
Kosuge, Tomoo
Kaneda, Takashi
Kato, Takao
Yagihara, Kazuhiro
Fujita, Shigeyuki
Huang, Wilber
Yamada, Tesshi
Tachikawa, Masanori
Terasaki, Tetsuya
author_sort Yoneyama, Toshihiro
collection PubMed
description Pancreatic cancer is one of the most lethal tumors, and reliable detection of early-stage pancreatic cancer and risk diseases for pancreatic cancer is essential to improve the prognosis. As 260 genes were previously reported to be upregulated in invasive ductal adenocarcinoma of pancreas (IDACP) cells, quantification of the corresponding proteins in plasma might be useful for IDACP diagnosis. Therefore, the purpose of the present study was to identify plasma biomarkers for early detection of IDACP by using two proteomics strategies: antibody-based proteomics and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics. Among the 260 genes, we focused on 130 encoded proteins with known function for which antibodies were available. Twenty-three proteins showed values of the area under the curve (AUC) of more than 0.8 in receiver operating characteristic (ROC) analysis of reverse-phase protein array (RPPA) data of IDACP patients compared with healthy controls, and these proteins were selected as biomarker candidates. We then used our high-throughput selected reaction monitoring or multiple reaction monitoring (SRM/MRM) methodology, together with an automated sample preparation system, micro LC and auto analysis system, to quantify these candidate proteins in plasma from healthy controls and IDACP patients on a large scale. The results revealed that insulin-like growth factor-binding protein (IGFBP)2 and IGFBP3 have the ability to discriminate IDACP patients at an early stage from healthy controls, and IGFBP2 appeared to be increased in risk diseases of pancreatic malignancy, such as intraductal papillary mucinous neoplasms (IPMNs). Furthermore, diagnosis of IDACP using the combination of carbohydrate antigen 19–9 (CA19-9), IGFBP2 and IGFBP3 is significantly more effective than CA19-9 alone. This suggests that IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of IDACP patients.
format Online
Article
Text
id pubmed-5007017
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50070172016-09-27 Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics Yoneyama, Toshihiro Ohtsuki, Sumio Honda, Kazufumi Kobayashi, Makoto Iwasaki, Motoki Uchida, Yasuo Okusaka, Takuji Nakamori, Shoji Shimahara, Masashi Ueno, Takaaki Tsuchida, Akihiko Sata, Naohiro Ioka, Tatsuya Yasunami, Yohichi Kosuge, Tomoo Kaneda, Takashi Kato, Takao Yagihara, Kazuhiro Fujita, Shigeyuki Huang, Wilber Yamada, Tesshi Tachikawa, Masanori Terasaki, Tetsuya PLoS One Research Article Pancreatic cancer is one of the most lethal tumors, and reliable detection of early-stage pancreatic cancer and risk diseases for pancreatic cancer is essential to improve the prognosis. As 260 genes were previously reported to be upregulated in invasive ductal adenocarcinoma of pancreas (IDACP) cells, quantification of the corresponding proteins in plasma might be useful for IDACP diagnosis. Therefore, the purpose of the present study was to identify plasma biomarkers for early detection of IDACP by using two proteomics strategies: antibody-based proteomics and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics. Among the 260 genes, we focused on 130 encoded proteins with known function for which antibodies were available. Twenty-three proteins showed values of the area under the curve (AUC) of more than 0.8 in receiver operating characteristic (ROC) analysis of reverse-phase protein array (RPPA) data of IDACP patients compared with healthy controls, and these proteins were selected as biomarker candidates. We then used our high-throughput selected reaction monitoring or multiple reaction monitoring (SRM/MRM) methodology, together with an automated sample preparation system, micro LC and auto analysis system, to quantify these candidate proteins in plasma from healthy controls and IDACP patients on a large scale. The results revealed that insulin-like growth factor-binding protein (IGFBP)2 and IGFBP3 have the ability to discriminate IDACP patients at an early stage from healthy controls, and IGFBP2 appeared to be increased in risk diseases of pancreatic malignancy, such as intraductal papillary mucinous neoplasms (IPMNs). Furthermore, diagnosis of IDACP using the combination of carbohydrate antigen 19–9 (CA19-9), IGFBP2 and IGFBP3 is significantly more effective than CA19-9 alone. This suggests that IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of IDACP patients. Public Library of Science 2016-08-31 /pmc/articles/PMC5007017/ /pubmed/27579675 http://dx.doi.org/10.1371/journal.pone.0161009 Text en © 2016 Yoneyama et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yoneyama, Toshihiro
Ohtsuki, Sumio
Honda, Kazufumi
Kobayashi, Makoto
Iwasaki, Motoki
Uchida, Yasuo
Okusaka, Takuji
Nakamori, Shoji
Shimahara, Masashi
Ueno, Takaaki
Tsuchida, Akihiko
Sata, Naohiro
Ioka, Tatsuya
Yasunami, Yohichi
Kosuge, Tomoo
Kaneda, Takashi
Kato, Takao
Yagihara, Kazuhiro
Fujita, Shigeyuki
Huang, Wilber
Yamada, Tesshi
Tachikawa, Masanori
Terasaki, Tetsuya
Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics
title Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics
title_full Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics
title_fullStr Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics
title_full_unstemmed Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics
title_short Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics
title_sort identification of igfbp2 and igfbp3 as compensatory biomarkers for ca19-9 in early-stage pancreatic cancer using a combination of antibody-based and lc-ms/ms-based proteomics
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007017/
https://www.ncbi.nlm.nih.gov/pubmed/27579675
http://dx.doi.org/10.1371/journal.pone.0161009
work_keys_str_mv AT yoneyamatoshihiro identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT ohtsukisumio identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT hondakazufumi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT kobayashimakoto identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT iwasakimotoki identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT uchidayasuo identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT okusakatakuji identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT nakamorishoji identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT shimaharamasashi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT uenotakaaki identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT tsuchidaakihiko identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT satanaohiro identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT iokatatsuya identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT yasunamiyohichi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT kosugetomoo identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT kanedatakashi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT katotakao identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT yagiharakazuhiro identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT fujitashigeyuki identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT huangwilber identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT yamadatesshi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT tachikawamasanori identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics
AT terasakitetsuya identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics